Adjuvant Temozolomide for IDH-Mutated Anaplastic Astrocytoma: Final CATNON Results Confirm a Decade of Survival Benefit
The final analysis of the EORTC CATNON trial reveals that 12 cycles of adjuvant temozolomide significantly extend overall survival to 12.5 years in IDH-mutated anaplastic astrocytoma, whereas concurrent temozolomide provides no added clinical benefit.
